메뉴 건너뛰기




Volumn 2, Issue 6, 2012, Pages 512-523

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; JANUS KINASE; JANUS KINASE 2; JANUS KINASE INHIBITOR; NVP BBT594; NVP BSK805; PROTEIN KINASE INHIBITOR; STAT5 PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG;

EID: 84865713305     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0324     Document Type: Article
Times cited : (108)

References (50)
  • 1
    • 0026081302 scopus 로고
    • Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase
    • Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991;11:2057-65.
    • (1991) Mol Cell Biol , vol.11 , pp. 2057-2065
    • Wilks, A.F.1    Harpur, A.G.2    Kurban, R.R.3    Ralph, S.J.4    Zurcher, G.5    Ziemiecki, A.6
  • 2
    • 0028268381 scopus 로고
    • Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases
    • Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett 1994;342:124-8.
    • (1994) FEBS Lett , vol.342 , pp. 124-128
    • Takahashi, T.1    Shirasawa, T.2
  • 3
    • 0025278593 scopus 로고
    • Identification and chromosomal mapping of new human tyrosine kinase genes
    • Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 1990;5:277-82.
    • (1990) Oncogene , vol.5 , pp. 277-282
    • Krolewski, J.J.1    Lee, R.2    Eddy, R.3    Shows, T.B.4    Dalla-Favera, R.5
  • 4
    • 80052492285 scopus 로고    scopus 로고
    • The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
    • Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011;18:971-6.
    • (2011) Nat Struct Mol Biol , vol.18 , pp. 971-976
    • Ungureanu, D.1    Wu, J.2    Pekkala, T.3    Niranjan, Y.4    Young, C.5    Jensen, O.N.6
  • 5
    • 0034012330 scopus 로고    scopus 로고
    • Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
    • Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20:3387-95.
    • (2000) Mol Cell Biol , vol.20 , pp. 3387-3395
    • Saharinen, P.1    Takaluoma, K.2    Silvennoinen, O.3
  • 6
    • 0028835347 scopus 로고
    • Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alphabbeta and for signal transduction
    • Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uzé G, Pellegrini S. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alphabbeta and for signal transduction. J Biol Chem 1995;270:3327-34.
    • (1995) J Biol Chem , vol.270 , pp. 3327-3334
    • Velazquez, L.1    Mogensen, K.E.2    Barbieri, G.3    Fellous, M.4    Uzé, G.5    Pellegrini, S.6
  • 7
    • 0038371050 scopus 로고    scopus 로고
    • Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain
    • Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003;14:1448-59.
    • (2003) Mol Biol Cell , vol.14 , pp. 1448-1459
    • Saharinen, P.1    Vihinen, M.2    Silvennoinen, O.3
  • 8
    • 0030953469 scopus 로고    scopus 로고
    • Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop
    • Feng J, Witthuhn B, Matsuda T, Kohlhuber F, Kerr I, Ihle J. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997;17:2497-501.
    • (1997) Mol Cell Biol , vol.17 , pp. 2497-2501
    • Feng, J.1    Witthuhn, B.2    Matsuda, T.3    Kohlhuber, F.4    Kerr, I.5    Ihle, J.6
  • 9
    • 14744299761 scopus 로고    scopus 로고
    • Turning cells red: Signal transduction mediated by erythropoietin
    • Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-55.
    • (2005) Trends Cell Biol , vol.15 , pp. 146-155
    • Richmond, T.D.1    Chohan, M.2    Barber, D.L.3
  • 10
    • 27144452311 scopus 로고    scopus 로고
    • JAK protein kinase inhibitors
    • Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005;18:305-10.
    • (2005) Drug News Perspect , vol.18 , pp. 305-310
    • Thompson, J.E.1
  • 11
    • 32144453842 scopus 로고    scopus 로고
    • JAK1STAT signal transduction: Regulators and implication in hematological malignancies
    • Valentino L, Pierre J. JAK1STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006;71:713-21.
    • (2006) Biochem Pharmacol , vol.71 , pp. 713-721
    • Valentino, L.1    Pierre, J.2
  • 12
    • 17844383458 scopus 로고    scopus 로고
    • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    • James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
    • (2005) Nature , vol.434 , pp. 1144-1148
    • James, C.1    Ugo, V.2    Le Couedic, J.-P.3    Staerk, J.4    Delhommeau, F.5    Lacout, C.6
  • 13
    • 20244369569 scopus 로고    scopus 로고
    • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    • Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
    • (2005) Cancer Cell , vol.7 , pp. 387-397
    • Levine, R.L.1    Wadleigh, M.2    Cools, J.3    Ebert, B.L.4    Wernig, G.5    Huntly, B.J.P.6
  • 14
    • 57749188299 scopus 로고    scopus 로고
    • Targeting cancer with small molecule kinase inhibitors
    • Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
    • (2009) Nat Rev Cancer , vol.9 , pp. 28-39
    • Zhang, J.1    Yang, P.L.2    Gray, N.S.3
  • 16
    • 0028223221 scopus 로고
    • Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program
    • Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 1994;45:673-83.
    • (1994) Mol Pharmacol , vol.45 , pp. 673-683
    • Posner, I.1    Engel, M.2    Gazit, A.3    Levitzki, A.4
  • 19
    • 79551575494 scopus 로고    scopus 로고
    • Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
    • Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127-40.
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 127-140
    • Quintás-Cardama, A.1    Kantarjian, H.2    Cortes, J.3    Verstovsek, S.4
  • 20
    • 33749239636 scopus 로고    scopus 로고
    • Gö6976 is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells
    • Grandage VL, Everington T, Linch DC, Khwaja A. Gö6976 is a potent inhibitor of the JAK2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006;135:303-16.
    • (2006) Br J Haematol , vol.135 , pp. 303-316
    • Grandage, V.L.1    Everington, T.2    Linch, D.C.3    Khwaja, A.4
  • 21
    • 69449087032 scopus 로고    scopus 로고
    • SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling
    • Haan S, Wuller S, Kaczor J, Rolvering C, Nocker T, Behrmann I, et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 2009;28:3069-80.
    • (2009) Oncogene , vol.28 , pp. 3069-3080
    • Haan, S.1    Wuller, S.2    Kaczor, J.3    Rolvering, C.4    Nocker, T.5    Behrmann, I.6
  • 22
    • 80755140046 scopus 로고    scopus 로고
    • SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
    • Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25:1751-9.
    • (2011) Leukemia , vol.25 , pp. 1751-1759
    • Hart, S.1    Goh, K.C.2    Novotny-Diermayr, V.3    Hu, C.Y.4    Hentze, H.5    Tan, Y.C.6
  • 23
    • 33644546402 scopus 로고    scopus 로고
    • JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
    • Quentmeier H, MacLeod RAF, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006;20:471-6.
    • (2006) Leukemia , vol.20 , pp. 471-476
    • Quentmeier, H.1    McLeod, R.A.F.2    Zaborski, M.3    Drexler, H.G.4
  • 25
    • 33746437130 scopus 로고    scopus 로고
    • MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
    • Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
    • (2006) PLoS Med , vol.3
    • Pikman, Y.1    Lee, B.H.2    Mercher, T.3    McDowell, E.4    Ebert, B.L.5    Gozo, M.6
  • 26
    • 70350519430 scopus 로고    scopus 로고
    • Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
    • Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009;114:2688-98.
    • (2009) Blood , vol.114 , pp. 2688-2698
    • Russell, L.J.1    Capasso, M.2    Vater, I.3    Akasaka, T.4    Bernard, O.A.5    Calasanz, M.J.6
  • 28
    • 70349232895 scopus 로고    scopus 로고
    • Selective reduction of JAK2V617F-dependent cell growth by siRNAa shRNA and its reversal by cytokines
    • Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil J-A, Casadevall N, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNAa shRNA and its reversal by cytokines. Blood 2009;114:1842-51.
    • (2009) Blood , vol.114 , pp. 1842-1851
    • Jedidi, A.1    Marty, C.2    Oligo, C.3    Jeanson-Leh, L.4    Ribeil, J-A.5    Casadevall, N.6
  • 30
    • 79953043687 scopus 로고    scopus 로고
    • Jak1 has a dominant role over Jak3 in signal transduction through c-containing cytokine receptors
    • Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, et al. Jak1 has a dominant role over Jak3 in signal transduction through c-containing cytokine receptors. Chem Biol 2011;18:314-23.
    • (2011) Chem Biol , vol.18 , pp. 314-323
    • Haan, C.1    Rolvering, C.2    Raulf, F.3    Kapp, M.4    Drückes, P.5    Thoma, G.6
  • 32
    • 77953872197 scopus 로고    scopus 로고
    • Rational design of T315I BCR-Abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML): BGG463
    • Manley PW, Brüggen J, Floersheimer A, Furet P, Jensen MR, Mestan J, et al. Rational design of T315I BCR-Abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML): BGG463. Chimia 2008;62:579.
    • (2008) Chimia , vol.62 , pp. 579
    • Manley, P.W.1    Brüggen, J.2    Floersheimer, A.3    Furet, P.4    Jensen, M.R.5    Mestan, J.6
  • 33
    • 30144436273 scopus 로고    scopus 로고
    • The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
    • Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107:176-83.
    • (2006) Blood , vol.107 , pp. 176-183
    • Lucet, I.S.1    Fantino, E.2    Styles, M.3    Bamert, R.4    Patel, O.5    Broughton, S.E.6
  • 35
    • 34548351250 scopus 로고    scopus 로고
    • Modulation of protein tyrosine phosphatase 1B by erythropoietin in UT-7 cell line
    • Callero M, Pérez G, Vittori D, Pregi N, Nesse A. Modulation of protein tyrosine phosphatase 1B by erythropoietin in UT-7 cell line. Cell Physiol Biochem 2007;20:319-28.
    • (2007) Cell Physiol Biochem , vol.20 , pp. 319-328
    • Callero, M.1    Pérez, G.2    Vittori, D.3    Pregi, N.4    Nesse, A.5
  • 36
    • 20244389693 scopus 로고    scopus 로고
    • The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop
    • Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-20.
    • (1999) EMBO J , vol.18 , pp. 1309-1320
    • Yasukawa, H.1    Misawa, H.2    Sakamoto, H.3    Masuhara, M.4    Sasaki, A.5    Wakioka, T.6
  • 37
    • 23044495944 scopus 로고    scopus 로고
    • Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog
    • Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005;106:996-1002.
    • (2005) Blood , vol.106 , pp. 996-1002
    • Boggon, T.J.1    Li, Y.2    Manley, P.W.3    Eck, M.J.4
  • 38
    • 0033522422 scopus 로고    scopus 로고
    • Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling
    • Takaoka A, Tanaka N, Mitani Y, Miyazaki T, Fujii H, Sato M, et al. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. EMBO J 1999;18:2480-8.
    • (1999) EMBO J , vol.18 , pp. 2480-2488
    • Takaoka, A.1    Tanaka, N.2    Mitani, Y.3    Miyazaki, T.4    Fujii, H.5    Sato, M.6
  • 39
    • 18244393495 scopus 로고    scopus 로고
    • Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for janus kinases
    • Zhou Y-J, Chen M, Cusack NA, Kimmel LH, Magnuson KS, Boyd JG, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for janus kinases. Mol Cell 2001;8:959-69.
    • (2001) Mol Cell , vol.8 , pp. 959-969
    • Zhou, Y-J.1    Chen, M.2    Cusack, N.A.3    Kimmel, L.H.4    Magnuson, K.S.5    Boyd, J.G.6
  • 40
    • 77955299093 scopus 로고    scopus 로고
    • JAK2 V617F constitutive activation requires JH2 residue F595: A pseudokinase domain target for specific inhibitors
    • Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 2010;5:e11157.
    • (2010) PLoS One , vol.5
    • Dusa, A.1    Mouton, C.2    Pecquet, C.3    Herman, M.4    Constantinescu, S.N.5
  • 41
    • 43549109620 scopus 로고    scopus 로고
    • The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
    • Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008;111:3751-9.
    • (2008) Blood , vol.111 , pp. 3751-3759
    • Wernig, G.1    Gonneville, J.R.2    Crowley, B.J.3    Rodrigues, M.S.4    Reddy, M.M.5    Hudon, H.E.6
  • 42
    • 63149194964 scopus 로고    scopus 로고
    • V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
    • Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009;106:4519-24.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 4519-4524
    • Pratilas, C.A.1    Taylor, B.S.2    Ye, Q.3    Viale, A.4    Sander, C.5    Solit, D.B.6
  • 43
    • 34547933680 scopus 로고    scopus 로고
    • Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition
    • Han EKH, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007;26:5655-61.
    • (2007) Oncogene , vol.26 , pp. 5655-5661
    • Han, E.K.H.1    Leverson, J.D.2    McGonigal, T.3    Shah, O.J.4    Woods, K.W.5    Hunter, T.6
  • 45
    • 0033965488 scopus 로고    scopus 로고
    • Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: Evidence for interactions between the kinase and pseudokinase domains
    • Chen M, Cheng A, Candotti F, Zhou Y-J, Hymel A, Fasth A, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000;20:947-56.
    • (2000) Mol Cell Biol , vol.20 , pp. 947-956
    • Chen, M.1    Cheng, A.2    Candotti, F.3    Zhou, Y-J.4    Hymel, A.5    Fasth, A.6
  • 46
    • 0030729823 scopus 로고    scopus 로고
    • Structural and functional basis for JAK3-deficient severe combined immunodeficiency
    • Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997;90:3996-4003.
    • (1997) Blood , vol.90 , pp. 3996-4003
    • Candotti, F.1    Oakes, S.A.2    Johnston, J.A.3    Giliani, S.4    Schumacher, R.F.5    Mella, P.6
  • 47
    • 54349086521 scopus 로고    scopus 로고
    • Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
    • Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-92.
    • (2008) Lancet , vol.372 , pp. 1484-1492
    • Bercovich, D.1    Ganmore, I.2    Scott, L.M.3    Wainreb, G.4    Birger, Y.5    Elimelech, A.6
  • 49
    • 77952338791 scopus 로고    scopus 로고
    • ErbB34 HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
    • Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB34 HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 2010;107:7692-7.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 7692-7697
    • Shi, F.1    Telesco, S.E.2    Liu, Y.3    Radhakrishnan, R.4    Lemmon, M.A.5
  • 50
    • 77950037732 scopus 로고    scopus 로고
    • Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors
    • Pissot-Soldermann C, Gerspacher M, Furet P, Gaul C, Holzer P, McCarthy C, et al. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett 2010;20:2609-13.
    • (2010) Bioorg Med Chem Lett , vol.20 , pp. 2609-2613
    • Pissot-Soldermann, C.1    Gerspacher, M.2    Furet, P.3    Gaul, C.4    Holzer, P.5    McCarthy, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.